Pierre Fabre Pharmaceuticals - Salamanca Free Press

$Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)$

Press Releases

Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Pierre Fabre Pharmaceuticals

December 7, 2024

Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a50.7%Objective ResponseRate (ORR), 23.0-month MedianDurationofResponse (DOR)...

Salamanca Press

Get in touch with The Salamanca Press

Submit Content

Advertise

Subscribe